JMJasmine Moshiri

Jasmine Moshiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jasmine Moshiri has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Pooled CRISPR Screen Reveals Genes Critical for Erythroblast Enucleation

    by Marilou Tetard, Tianjian Lin, Nana A. Peterson, Rebekah C. Gullberg, Yann Le Guen, Jasmine Moshiri, John G. Doench, Elizabeth S. Egan

    Terminal erythroid differentiation involves dramatic cellular remodeling that culminates in the expulsion of the nucleus, a process known as enucleation. While enucleation is conserved across mammals and is crucial for the generation of fully functional erythrocytes, the mechanisms governing this process have remained largely unknown, in part because the absence of genetic material in mature, enucleated red blood cells hinders genetic experimentation. Here, we performed a pooled, forward‐genetic CRISPR‐Cas9 screen in enucleated red blood cells derived from primary human hematopoietic stem/progenitor cells to identify genes required for enucleation. We found that Chloride Intracellular Channel 3 (CLIC3) and Vesicle‐associated membrane protein 8 (VAMP8) are both necessary for terminal erythroid differentiation, yet likely act through different mechanisms. Knockdown of CLIC3 led to a delay in erythroblast differentiation, culminating in impaired enucleation. We found that the knockdown cells had increased p53 and p21 and exhibited cell cycle alterations, suggesting CLIC3 plays a crucial role in coordinating cell cycle progression during erythropoiesis. In comparison, VAMP8‐depleted cells accumulated at the orthochromatic erythroblast stage and displayed a specific defect in enucleation. Transcriptional analysis of the VAMP8‐knockdown cells suggested dysregulation of pathways for vesicle trafficking and actin binding, and imaging of late‐stage erythroblasts revealed impaired nuclear polarization and disorganized actin. This work provides a new approach for functional genomics in enucleated cells and reveals novel factors important for terminal erythroid differentiation and enucleation.

  • Open Access

    Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19

    by Lauren Rodriguez, Kristen Andreatta, Shuguang Chen, Yu Hu, Jiani Li, Ross Martin, Dong Han, Jasmine Moshiri, Jason K. Perry, Meghan E. Sise, et al.

    Remdesivir inhibits the SARS-CoV-2 RNA-dependent polymerase (Nsp12). Here, we present virology analyses from the Phase 3 REDPINE trial in participants with impaired kidney function hospitalized for COVID-19 and treated with remdesivir or placebo for 5 days. Out of 243 participants enrolled and treated in the study, 42 participants had solid organ transplantation (SOT) and received immunosuppressive medication prior to and during the study. Nasopharyngeal swabs were collected at baseline and through Day 29. Virology assessments were performed using SARS-CoV-2 RT-qPCR, next-generation sequencing, and site-directed mutagenesis in a SARS-CoV-2 replicon system. Remdesivir treatment demonstrated significantly greater reductions from baseline in viral load on Day 5 and Day 7 compared with placebo ( P ≤ 0.034). In the remdesivir treatment group, participants with SOT showed significantly smaller viral load reductions from baseline on Days 5, 7, and 14 compared with participants without SOT (all P < 0.05). Mathematical modeling of viral load kinetics in participants with kidney transplants predicted a >13-day faster time to viral load decline by extending the remdesivir treatment duration from 5 days to 10 days. In four participants treated with remdesivir, emergent substitutions in Nsp12 (E136V, M794I, and C799F) with low-level reduced in vitro susceptibility to remdesivir (≤3.4 fold change in half-maximal effective concentration) were observed 9 days after cessation of remdesivir treatment. Three of the four participants had undergone SOT. Overall, remdesivir demonstrated antiviral activity in participants with impaired kidney function, with delayed viral clearance in SOT recipients and rare posttreatment emergence of Nsp12 substitutions that confer low-level reduced susceptibility to remdesivir. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04745351 ; EudraCT registration no. 2020-005416-22.

  • Open Access

    Mechanosensitive extrusion of Enterovirus A71-infected cells from colonic organoids

    by Jasmine Moshiri, Ailsa R. Craven, Sara B. Mixon, Manuel R. Amieva, Karla Kirkegaard

    Enterovirus A71 causes severe disease upon systemic infection, sometimes leading to life-threatening neurological dysfunction. However, in most cases infection is asymptomatic and limited to the gastrointestinal tract, where virus is amplified for transmission. Picornaviruses have previously been shown to exit infected cells via either cell lysis or secretion of vesicles. Here we report that entire Enterovirus A71-infected cells are specifically extruded from the apical surface of differentiated human colon organoids, as observed by confocal microscopy. Differential sensitivity to chemical and peptide inhibitors demonstrated that extrusion of virus-infected cells is dependent on force sensing via mechanosensitive ion channels rather than apoptotic cell death. When isolated and used as inoculum, intact virus-containing extruded cells can initiate new infections. In contrast, when mechanical force sensing is inhibited, large amounts of free virus are released. Thus, extrusion of live, virus-infected cells from intact epithelial tissue is likely to benefit both the integrity of host tissues and the protected spread of this faecal–oral pathogen within and between hosts.


  • Open Access

    A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity

    by Jasmine Moshiri, David A. Constant, Bowen Liu, Roberto Mateo, Steven Kearnes, Paul Novick, Ritika Prasad, Claude Nagamine, Vijay Pande, Karla Kirkegaard

    Affordable and effective antiviral therapies are needed worldwide, especially against agents such as dengue virus that are endemic in underserved regions. Many antiviral compounds have been studied in cultured cells but are unsuitable for clinical applications due to pharmacokinetic profiles, side effects, or inconsistent efficacy across dengue serotypes. Such tool compounds can, however, aid in identifying clinically useful treatments. Here, computational screening (Rapid Overlay of Chemical Structures) was used to identify entries in an in silico database of safe-in-human compounds (SWEETLEAD) that display high chemical similarities to known inhibitors of dengue virus. Inhibitors of the dengue proteinase NS2B/3, the dengue capsid, and the host autophagy pathway were used as query compounds. Three FDA-approved compounds that resemble the tool molecules structurally, cause little toxicity, and display strong antiviral activity in cultured cells were selected for further analysis. Pyrimethamine (50% inhibitory concentration [IC50] = 1.2 μM), like the dengue proteinase inhibitor ARDP0006 to which it shows structural similarity, inhibited intramolecular NS2B/3 cleavage. Lack of toxicity early in infection allowed testing in mice, in which pyrimethamine also reduced viral loads. Niclosamide (IC50 = 0.28 μM), like dengue core inhibitor ST-148, affected structural components of the virion and inhibited early processes during infection. Vandetanib (IC50 = 1.6 μM), like cellular autophagy inhibitor spautin-1, blocked viral exit from cells and could be shown to extend survival in vivo. Thus, three FDA-approved compounds with promising utility for repurposing to treat dengue virus infections and their potential mechanisms were identified using computational tools and minimal phenotypic screening. IMPORTANCE No antiviral therapeutics are currently available for dengue virus infections. By computationally overlaying the three-dimensional (3D) chemical structures of compounds known to inhibit dengue virus over those of compounds known to be safe in humans, we identified three FDA-approved compounds that are attractive candidates for repurposing as antivirals. We identified targets for two previously identified antiviral compounds and revealed a previously unknown potential anti-dengue compound, vandetanib. This computational approach to analyze a highly curated library of structures has the benefits of speed and cost efficiency. It also leverages mechanistic work with query compounds used in biomedical research to provide strong hypotheses for the antiviral mechanisms of the safer hit compounds. This workflow to identify compounds with known safety profiles can be expanded to any biological activity for which a small-molecule query compound has been identified, potentially expediting the translation of basic research to clinical interventions.


  • Open Access

    A targeted computational screen of the SWEETLEAD database reveals FDA-approved compounds with anti-dengue viral activity

    by Jasmine Moshiri, David A. Constant, Bowen Liu, Roberto Mateo, Stephen Kearnes, Paul Novick, Ritika Prasad, Claude Nagamine, Vijay Pande, Karla Kirkegaard

    Affordable and effective antiviral therapies are needed worldwide, especially against agents such as dengue virus that are endemic in underserved regions. Many antiviral compounds have been studied in cultured cells but are unsuitable for clinical applications due to pharmacokinetic profiles, side effects, or inconsistent efficacy across dengue serotypes. Such tool compounds can, however, aid in identifying clinically useful treatments. Here, computational screening (Rapid Overlay of Chemical Structures) was used to identify entries in an in silico database of safe-in-human compounds (SWEETLEAD) that display high chemical similarities to known inhibitors of dengue virus. Molecules known to inhibit dengue proteinase NS2B/3, dengue capsid, and the host autophagy pathway were used as query compounds. Following computational and initial virological screening, three FDA-approved compounds that resemble the tool molecules structurally, cause little toxicity and display strong antiviral activity in cultured cells were selected for further analysis. Pyrimethamine (IC 50 = 1.2 µM), like the dengue proteinase inhibitor ARDP0006 to which it shows structural similarity, inhibited intramolecular NS2B/3 cleavage. Lack of toxicity allowed testing in mice, in which pyrimethamine also reduced viral loads. Niclosamide (IC 50 = 0.28 µM), like dengue core inhibitor ST-148, affected structural components of the virion and inhibited early processes during infection. Vandetanib (IC 50 = 1.6 µM), like cellular autophagy inhibitor spautin-1, blocked viral exit from cells and could further be shown to extend survival in vivo . Our approach confirmed previous studies which used extensive high-throughput screening to identify niclosamide and pyrimethamine as antivirals, and it also revealed their likely molecular targets. Thus, three FDA-approved compounds with promising utility for repurposing to treat dengue virus infections and their potential mechanisms were identified using computational tools and minimal phenotypic screening. Author Summary: No antiviral therapeutics are currently available for dengue virus infections. By computationally overlaying the 3D chemical structures of compounds known to inhibit dengue virus with those of compounds known to be safe in humans, we identified three FDA-approved compounds that are attractive candidates for drug repurposing towards treatment of dengue virus infections. We identified potential targets of two previously identified antiviral compounds and revealed a previously unknown potential anti-dengue drug, vandetanib. This computational approach to analyze a highly curated library of structures has the benefits of speed and cost efficiency. It also leverages mechanistic work with query compounds used in biomedical research to provide strong hypotheses for the antiviral mechanisms of the safer hit compounds. This workflow to identify compounds with known safety profiles in humans can be expanded to any biological activity for which a small-molecule query compound has been identified, potentially expediting the translation of basic research to clinical interventions.